Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single center phase I study of ANB-030 single and multiple ascending dose cohorts

Next Previous
X
Search
Trial Profile

A single center phase I study of ANB-030 single and multiple ascending dose cohorts

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosnilimab (Primary) ; Rosnilimab (Primary)
  • Indications Alopecia areata; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio

    • Most Recent Events

    • 01 Jun 2024 According to an AnaptysBio media release, data from this trial were presented at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting.
    • 01 May 2024 According to an AnaptysBio media release, data from this trial presented at the 2024 Digestive Disease Week (DDW) Annual Meeting.
    • 15 Nov 2023 Results assessing the safety, pharmacokinetics and TPD activity of Rosnilimab in healthy volunteers, presented at the ACR Convergence 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top